Salud financiera de hoja de balance de Healius

Salud financiera controles de criterios 3/6

Healius tiene un patrimonio de accionistas total de A$1.1B y una deuda total de A$412.7M, lo que sitúa su ratio deuda-patrimonio en 39.3%. Sus activos y pasivos totales son A$3.0B y A$2.0B respectivamente. El BAIT de Healius es de A$74.4M, por lo que su ratio de cobertura de intereses es de 1.1. Tiene efectivo e inversiones a corto plazo que ascienden a A$85.7M.

Información clave

39.3%

Ratio deuda-patrimonio

AU$412.70m

Deuda

Ratio de cobertura de intereses	1.1x
Efectivo	AU$85.70m
Patrimonio	AU$1.05b
Total pasivo	AU$1.97b
Activos totales	AU$3.02b

Actualizaciones recientes sobre salud financiera

Here's Why Healius (ASX:HLS) Can Manage Its Debt Responsibly

Dec 02

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$314.8M) de HLS no cubren sus pasivos a corto plazo (A$596.9M).

Pasivo a largo plazo: Los activos a corto plazo (A$314.8M) de HLS no cubren sus pasivos a largo plazo (A$1.4B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (31.1%) de HLS se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de HLS ha crecido de 37.2% a 39.3% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: Aunque no es rentable HLS tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.

Pronóstico de cash runway: HLS no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 22.9% al año.

Salud financiera de hoja de balance de Healius

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Here's Why Healius (ASX:HLS) Can Manage Its Debt Responsibly

Recent updates

High number of new directors

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Australian Clinical Labs Limited (ASX:ACL) cancelled the acquisition of Healius Limited (ASX:HLS) from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.

New minor risk - Shareholder dilution

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited, Annual General Meeting, Nov 01, 2023

Australian Clinical Labs Limited (ASX:ACL) canceled the acquisition of Healius Limited (ASX:HLS)

Healius Limited Appoints Michael Stanford as Director

Full year 2023 earnings: Revenues miss analyst expectations

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 37%

Consensus EPS estimates fall by 37%

Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023

Consensus EPS estimates increase by 34%

Consensus EPS estimates increase by 36%

Consensus EPS estimates increase by 22%

High number of new directors

Consensus EPS estimates increase by 18%

Is Healius Limited (ASX:HLS) Trading At A 50% Discount?

Independent Non Executive Chairman recently bought AU$103k worth of stock

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Consensus EPS estimates increase by 17%

Healius Limited Announces Resignation of Alison Stephenson as Company Secretary

Consensus EPS estimates fall by 21%

At AU$3.07, Is It Time To Put Healius Limited (ASX:HLS) On Your Watch List?

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Consensus forecasts updated

Price target decreased to AU$3.23

Consensus EPS estimates fall by 13%

Nexus Hospitals entered into an agreement to acquire Montserrat Healthcare Pty Ltd from Healius Limited (ASX:HLS).

Here's Why Healius (ASX:HLS) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 27%

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

MD, CEO & Director recently sold AU$660k worth of stock

Is Now An Opportune Moment To Examine Healius Limited (ASX:HLS)?

Brookfield Reportedly Drops Out of Race to Buy Healius

Independent Non Executive Director recently bought AU$86k worth of stock

Non Executive & Independent Director recently bought AU$70k worth of stock

MD, CEO & Director exercised options to buy AU$2.2m worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Healius Limited Announces Fully Franked Ordinary Paid Dividend for the Six Months Ended June 30, 2022, Payable on September 21, 2022

Healius Limited, Annual General Meeting, Oct 20, 2022

Are Investors Undervaluing Healius Limited (ASX:HLS) By 48%?

Healius Reportedly Launches Day Surgery Sale Process

Price target decreased to AU$4.30

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Consensus EPS estimates fall by 13%

Healius Limited to Report Fiscal Year 2022 Results on Aug 31, 2022

Why Healius Limited (ASX:HLS) Could Be Worth Watching

Healius Reportedly Seeks X-Ray Factor in Day Surgeries Sale Plan

Healius Limited's (ASX:HLS) Prospects Need A Boost To Lift Shares

Healius Limited Announces Appointment of John Mattick as Non-Executive Director

Upcoming dividend of AU$0.10 per share

Consensus EPS estimates fall by 11%

Price target decreased to AU$4.94

Healius (ASX:HLS) Is Paying Out A Larger Dividend Than Last Year

First half 2022 earnings: EPS and revenues miss analyst expectations

Healius Limited Announces Ordinary Fully Paid Dividend for the Period of Six Months December 31, 2021, Payable April 15, 2022

Healius Limited to Report First Half, 2022 Results on Feb 23, 2022

Healius Limited (ASX:HLS) acquired Agilex Biolabs Pty Ltd.

Consensus EPS estimates increase by 20%

Healius Limited (ASX:HLS) entered into an agreement to acquire Agilex Biolabs Pty Ltd for approximately AUD 300 million.

MD, CEO & Director recently sold AU$713k worth of stock

Upcoming dividend of AU$0.068 per share

Full year 2021 earnings released: EPS AU$0.11 (vs AU$0.12 in FY 2020)

Healius Limited (ASX:HLS) acquired Axis Diagnostic Holdings Pty Limited.

Healius Reportedly to Sale Day Surgeries

Healius Limited Decides Not to Provide Earnings Guidance for the Second Half of 2021